October
2004 | Vol. 3, No. 12
1 AMA PRA Category 1 Credit
Table of Contents
A Patient With Estrogen Receptor–Positive
Breast Cancer Treated With Neoadjuvant Anastrozole
Susana N. Banerjee, MA (Cantab), MRCP
Ian E. Smith, MD, FRCP, FRCPE
Learning Objectives | Back to top
Upon completion of this learning material, physicians should be able to:
- Discuss results of recent studies examining the use of antiaromatase agents in the neoadjuvant treatment of breast cancer
- Compare the efficacy and toxicity of preoperative chemotherapy to those of hormonal neoadjuvant therapy
Activity Goals | Back to top
Each year, more than 200,000 new cases of breast cancer will be diagnosed in the United States alone. There is an increasing trend toward detection of tumors at an earlier stage, allowing breast-conserving surgery to be used more frequently, but in many cases tumor size or locally-advanced disease precludes surgery. Preoperative or neoadjuvant chemotherapy has been used to shrink tumors before surgery but is associated with significant toxicities. However, since many tumors require estrogen for their growth, endocrine manipulation provides an alternate, less toxic strategy for neoadjuvant therapy. Agents that inhibit or inactivate the enzyme aromatase, a key source of estrogen production in postmenopausal women, have been tested recently in this setting.
The purpose of this activity is to review the efficacy of antiaromatase agents in the neoadjuvant treatment of breast cancer.
Target Audience | Back to top
This publication is intended for medical oncologists involved in the care of patients with breast cancer. No specific skills or knowledge other than a basic training in oncology are required for successful participation in this activity.
Accreditation | Back to top
Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Release date: October 31, 2004 Expiration date: October 31, 2005
Disclosure Policy | Back to top
As a sponsor accredited by the Accreditation Council for Continuing Medical Education, Physicians’ Education Resource must ensure balance, independence, objectivity and scientific rigor in all its sponsored activities. All faculty participating in a sponsored activity are expected to disclose to the activity audience any significant financial interest or other relationship (1) with the manufacturer(s) of any commercial product(s) and (2) with any commercial supporters of the activity. (Significant financial interest or other relationships can include such things as grants or research support, employee, consultant, major stockholder, member of speaker’s bureau, etc.) The intent of this disclosure is not to prevent an author with a significant financial or other relationship from publishing an article, but rather to provide readers with information on which they can make their own judgements. It remains for the readers to determine whether the author’s interests or relationships may influence the publication with regard to exposition or conclusion.
Susana N. Banerjee, MA (Cantab), MRCP
Has nothing to disclose
Ian E. Smith, MD, FRCP, FRCPE
Grant or Research Support – AstraZeneca
Speaker’s Bureau – AstraZeneca
The article in this CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the article includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the article page. Please refer to the full prescribing information for each drug discussed in this newsletter for FDA-approved dosing, indications, and warnings.
Cover Illustration | Back to top
Ultrasound scans of a 66-year-old woman with estrogen receptor–positive breast cancer showing a large irregular breast mass measuring 6.0 x 5.0 cm (top panel) but no measurable residual tumor after 12 weeks of treatment with neoadjuvant anastrozole (bottom panel)
Case Studies in Breast Cancer (ISSN: 1539-817X) is produced by Physicians’ Education Resource, Dallas, TX. An unrestricted educational grant for this publication was provided by AstraZeneca.
The views and opinions expressed in this publication are those of the authors and do not necessarily reflect the views of the sponsor or publisher. Although great care has been taken in compiling and checking the information given in this publication to ensure accuracy, the authors, AstraZeneca, and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this publication, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.
Please consult full prescribing information for any drugs or procedures discussed within.
All rights reserved. No part of this publication may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.
©Copyright 2004 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.
All correspondence should be directed to:
Editor, Case Studies in Breast Cancer
Physicians’ Education Resource
3535 Worth St.
Suite 4802
Dallas, TX 75246
Phone: (214) 820-8079
Fax: (214) 820-8844
E-mail: editor@perlp.com
Editorial Staff:
Publishing Manager – B. Diane Gambill, PhD
Assistant Publishing Manager – David Lee, PhD
Managing Editor – Jennifer Klem, PhD
Manager, CME and Content – Preeta Tyagi, PhD
Senior Medical Editor – Jay Delmar, PhD
Associate Medical Editor – Jill Cowherd
Medical Editor/Proofreader – Pete Sloan
Acquisitions – Anissa Mitchell
Design & Production:
Art Director – Todd J. Hagler
Senior Graphic Artist – Kelly D. Martin
Graphic Artist – Kevin Graves
ISSN: 1539-817X
Back to top
|
